BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
Visit company website
5 years, 5 months ago
BioSyent Inc is currently in a long term uptrend where the price is trading 3.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
BioSyent Inc's total revenue rose by 2.8% to $6M since the same quarter in the previous year.
Its net income has dropped by 43.0% to $666K since the same quarter in the previous year.
Finally, its free cash flow fell by 37.0% to $2M since the same quarter in the previous year.
Based on the above factors, BioSyent Inc gets an overall score of 3/5.